Articles tagged with Pharmaceutical Industry
Scientists at University of Limerick are teaming up with Enterprise Ireland to commercialize continuous nanomanufacturing technology. The project aims to tackle the biggest challenge facing the pharmaceutical industry today, which is that seven out of ten drugs never reach patients due to poor solubility.
Researchers at KAUST and TUM have successfully identified and characterized an enzyme from a brine pool in the Red Sea, which shows promising characteristics for commercial use. The study uses single-amplified genomes to produce proteins and provides a roadmap for mining molecular riches of extreme environments.
Clinical commissioning groups in England received over £3.7 million in payments from drug companies that were not disclosed to patients and the public. The findings show that only two-thirds of payments and a quarter of their value were listed in registers or declarations published by CCGs.
The 2017 WRIB White Papers cover topics such as LCMS small molecules, hybrid LBA/LCMS biotherapeutics, and immunogenicity assays. An interactive Decennial Index of the White Papers provides a decade-long overview of recommendations on bioanalysis and biomarkers.
Researchers at RUDN University have developed a way to produce benzofurans, a key component in various pharmaceutical substances, from cheap agricultural and woody waste. The new approach uses salicyl alcohols derived from low-cost chemicals, enabling the creation of new benzofuran-based drug substances.
A study by University of Toronto professors found that approximately half of the editors of influential medical journals received payments from the pharmaceutical and medical device industry in 2014. The authors believe that similar policies for journal editors should be implemented to address conflicts of interest.
The Science/Science Careers' 2017 Top Employers Survey ranked Regeneron the top biopharmaceutical employer, followed by Biogen and Pfizer. The survey received over 6,950 responses from employees in biotechnology, biopharmaceutical, and pharmaceutical companies worldwide.
The Center for Biorenewable Chemicals (CBiRC) at Iowa State University has introduced a new model for developing biorenewable technologies. By identifying 'bioprivileged molecules' with unique properties, researchers aim to create value from biomass and expand the bioproduct horizon beyond petrochemicals.
A research team led by Professor Bhesh Bhandari has discovered that small fat globules can impart stability to cream and give cold butter a softer texture. The breakthrough uses nanoemulsions to create innovative dairy ingredients with potential to increase the return on investment for dairy manufacturers.
The special focus issue of Bioanalysis examines models and trends in outsourcing, featuring insights from key opinion leaders. The issue highlights the rapidly evolving aspect of drug discovery and development.
A new study by UC San Francisco researchers found that tobacco companies knew NRT hardly ever works without counseling, but now sell it over-the-counter to complement smoking. The 'Tobacco Papers' reveal how industry documents show a shift in perception toward nicotine.
Researchers at ETH Zurich have created a new type of silica particle that can stabilize both oil-in-water and water-in-oil emulsions using a single type of emulsifier. The particles' rough surface reduces their mobility, allowing them to form a stabilizing armour around droplets.
Rippleshot uses machine learning and data analytics to detect payment-card fraud, identifying at-risk cards and suggesting counteractions to prevent loss. The Innovate Indiana Fund investment will help expand the company's technical team and product offerings for merchants and banks.
A new study found that 65% of patients visited a doctor who received payments from pharmaceutical or medical device companies within the last year. Only 5% of those surveyed knew about their doctor's payments, highlighting a need for transparency and patient awareness.
A recent survey found that 65 percent of respondents had visited a physician who accepted industry payments, while only 5 percent knew if their own doctor received such favors. The study highlights the need for greater transparency in medical practices.
A study reveals widespread conflicts of interest among US-based patient-advocacy organizations, including funding from industry makers and board members with ties to pharmaceutical companies. The findings highlight the need for laws forcing organizations to disclose these connections.
The high cost of drugs has soured public sentiment towards the industry. Industry experts argue that more transparency and perspective are needed to understand the complex reasons behind price hikes.
A growing body of evidence suggests that patient advocacy groups funded by pharmaceutical companies may promote treatments that serve the companies' interests rather than patients' needs. Studies have found that these groups are often biased towards funding sources, with some reporting pressure to conform to industry positions.
A study by Michigan State University found that investors can only accurately predict product performance 48-55% of the time after a preannouncement. Researchers discovered certain conditions, such as detailed and truthful preannouncements in less competitive industries, can improve stock market reactions to preannouncements.
Key findings from 2016 pharmaceutical industry news include the fight against Zika and rare diseases, as well as failed deals and new players. The industry's top stories set the stage for 2017 with a focus on innovative treatments and regulatory changes.
Professor Rasmus Bro receives the first Nils Foss Excellence Prize for his groundbreaking work in process analytical technology (PAT) in the food industry. He has developed methods to analyse complex fluorescence data, revolutionizing water quality measurement.
A new study analyzed industry payments to 8,333 dermatologists in 2014, finding that the top 10% collected at least $3,940 and the top 1% received over $93,622. The majority of payments were for speaker fees, consulting, or research activities.
The John Innes Centre has developed a comprehensive online training hub for wheat researchers, providing essential information on experimental protocols, genomics tools, and cultivation techniques. The platform aims to break down barriers to wheat research, enabling new scientists to transition into the field.
The global seaweed industry is driving growth with valuable uses in food, fertilizer, pharmaceuticals, and industrial products. However, rapid expansion poses ecological and societal risks, including disease outbreaks and environmental degradation.
A study found that nearly nine out of ten physicians and researchers who developed leading cancer care guidelines in the US reported financial ties to the pharmaceutical and medical device industries. The majority of payments were within limits set by the NCCN, but eight guideline authors exceeded them.
Researchers at John Innes Centre discover a key 'twist' in producing heteroyohimbine compounds, which could lead to new and effective pharmaceuticals. The study reveals the importance of specific amino acid sequences in controlling stereoselectivity during compound synthesis.
Researchers have discovered a way to custom-build valuable triterpenes using 'chemical origami', a process inspired by the ancient Japanese art of origami. By modifying an enzyme called SAD1, they can produce different triterpene scaffolds and building blocks, leading to new medicines and industrial chemicals.
The 2016 Blavatnik National Awards recognize David Charbonneau's exoplanet discoveries, Phil Baran's natural product synthesis research, and Michael Rape's fundamental discoveries in ubiquitylation. The three Laureates receive $250,000 cash awards to support their future work.
A study found that physicians who received pharmaceutical industry-sponsored meals were more likely to prescribe certain brand-name drugs, with the rate increasing with the number and cost of meals. The study highlights concerns about the potential influence of industry payments on prescribing patterns.
The National Cell Manufacturing Consortium has developed a national roadmap for advanced cell manufacturing, aiming to increase the production of high-quality living cells for cell-based therapies. The consortium, established by Georgia Tech and industry partners, aims to establish the US as a leader in cell therapy manufacturing.
Researchers at ETH Zurich successfully upgraded methane into methyl bromide, a base material for fuels and chemicals, through oxybromination chemistry. The new catalyst, vanadium phosphate, enables closed-bromine recycling, making the process more efficient and environmentally friendly.
York University researchers have received a $1.7 million grant to develop a platform that rapidly determines detailed information about biologic drug candidates. The project aims to accelerate and improve the quality of pharmaceutical companies' drug discovery and development processes.
Scientists at Scripps Research Institute have developed a new electrochemistry-based method for allylic oxidation reactions, which are used in pharmaceuticals, flavor, and fragrance industries. The new method uses inexpensive, safe chemicals and is scalable, producing better yields and reducing toxic waste.
Patients undergoing parathyroid surgery experienced fewer hip fractures and fractures of any type compared to those receiving bisphosphonates. Surgery also improved bone mineral density, while bisphosphonates had no impact on fracture risk.
A new study from the University of Sydney found that medical device and pharmaceutical companies interact with nurses, who have significant influence over hospital purchasing decisions. Nurses reported receiving gifts, product samples, and paid travel, and most acknowledged benefits in working with industry representatives.
Researchers at RMIT University have developed a method to grow nanostructures that degrade organic matter when exposed to light, directly onto textiles. The technology has the potential to create fully self-cleaning textiles that can spontaneously clean stains and grime with minimal effort.
Researchers from the University of Surrey have discovered a new physical mechanism that separates particles according to their size during the drying of wet coatings. This 'self-layering' process creates two layers with independent properties, which could improve the performance of coatings across industries.
Researchers at the University of Huddersfield have pioneered sugar-powered catalysis, which could revolutionize industries such as agro-chemistry and pharmaceuticals. By harnessing the reducing potential of renewable sugars, scientists have developed a cost-effective and environmentally friendly method for catalysis.
A study by Temple University researchers found that pharmaceutical companies can improve their performance by investing in commercial innovation and aligning their culture of execution. The study, published in the Journal of Medical Marketing, analyzed data from 26 large and medium-sized pharmaceutical companies.
Researchers have developed new humidity sensors with antibacterial properties to prevent biofilm formation and biofouling in high-humidity environments. The sensors combine nanotechnology and fibre optics, offering biocompatibility, low cost, and long-distance measuring capabilities.
The TPP may drive up pharmaceutical prices in low-income countries, diminishing access to essential medications. The agreement also raises concerns about individual country litigation against multi-national pharmaceutical companies.
Researchers at MIT Portugal have created eco-friendly green detergents using biosurfactants derived from lignocellulosic biomass, offering advantages in bio-degradability and non-toxicity. The technology reduces costs of raw materials and environmental impact on production, providing a cleaner alternative for home and industrial use.
The number of NIH-funded trials decreased by 328, while industry-funded trials increased by 1,965, during the period. The total number of newly registered trials increased by 5,410, with industry-funded trials accounting for the majority of growth.
Scientists have identified the 3D structure of iridoid synthase, an enzyme crucial for producing anticancer and antimalarial compounds from plant natural products. The discovery provides insights into the biosynthesis process, shedding light on the unique mechanism used by this enzyme to generate core iridoid structures.
A new study reveals that nearly 1 in 10 healthcare company board positions are held by top academics from renowned medical institutions. These directors receive significant compensation, including annual payments of $193,000 and stock options, posing major individual and institutional conflict of interests.
The MIT, Broad Institute Foundry aims to revolutionize genetic engineering by enabling the rapid design, testing, and fabrication of large sequences of genetic information. The facility collaborates with academic and industrial partners to develop innovative pipeline tools for efficient and precise DNA design.
Researchers at the John Innes Centre found that Euglena gracilis has over 32,000 active protein-encoding genes, significantly more than humans. The single cell algae can produce various natural compounds, including vitamins, essential amino acids, and a sugar polymer with anti-HIV effects.
Researchers at Queensland University of Technology (QUT) have developed a new genetic technique using CRISPR-Cas9 to improve the nutritional value of feed for livestock. The method generates specific yeast that combine protein with digestive enzymes, reducing the need for supplements.
A Maine algal cluster will be formed to capitalize on growing business opportunities in the sustainable energy and food industries. The cluster aims to develop an implementation roadmap to grow the industry and promote a Maine Algae brand.
Yale University chemists have developed a family of new palladium-based catalysts, expected to lower production costs and boost sustainability. These catalysts create a better infrastructure for catalysis, reducing the need for expensive metals.
The pharmaceutical industry's regulatory system is criticized for lacking accountability and being evidence-based, resulting in high NHS costs and inefficient use of technology appraisal work. The Cancer Drugs Fund is also singled out for criticism due to its inequitable allocation of funds and discrimination against other diseases.
Researchers at the Austrian Centre of Industrial Biotechnology successfully produced large quantities of Nootkatone, a natural flavoring substance used in soft drinks and cosmetics. The substance was produced from sugar using genetic engineering in yeast cells, offering an environmentally friendly alternative to chemical synthesis.
The Austrian Centre of Industrial Biotechnology has developed the world's first continuous purification method for recombinant antibodies from clarified CHO cultures. This breakthrough technology is expected to significantly reduce production costs for highly valued drugs, such as cancer treatments and autoimmune disease therapies. The...
A study published in PLOS Medicine found that pharmaceutical industry self-regulation in the UK and Sweden had significant violations, with nearly 20% of cases being serious breaches. The researchers analyzed complaints and rulings to find that charges incurred by companies were a small percentage of annual sales revenue.
Public health scientists receiving funding from companies like Coca-Cola and Mars have also advised on nutritional guidance, raising questions about bias and conflict of interest. Research funded by the sugar industry has been linked to obesity crisis solutions.
A recent study found that the US rate of investment in medical research declined from 2004 to 2012, while global investment increased, especially in Asia. The share of US medical research funding from industry grew from 46% to 58%, favoring biotechnology and pharmaceutical industries.
The pharmaceutical industry has stepped up its efforts to improve access to medicine in developing countries, with many companies introducing innovative access-oriented business models and expanding generic version production. Despite progress, some companies lag behind, including Sanofi and Pfizer, which fell down the rankings signifi...
Scientists from the John Innes Centre are developing a new business concept to revive heritage lines of barley for brewing, offering greater choice and added value to farmers and brewers. The venture aims to provide sustainable production and high-quality malting barley, capitalizing on the demand for unique beer ingredients.
A Roundtable Discussion explores the application of novel toxicology models to predict adverse health effects and environmental exposures. The discussion covers human cell models, high-throughput screening methods, and three-dimensional tissue culture models.
As global poverty rates decrease, new challenges emerge in addressing rising healthcare costs and demands. Hans Rosling argues that verifiable data and statistics are essential for strategic decisions, and innovative solutions like generic drug production can make treatment more affordable for all.